Dolores M. Shoback

Dolores M. Shoback

Auto-generated profile, based on publicly available information

Dolores M. Shoback

University of California, San Francisco

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
DSDolores Shoback
Dolores Shoback
A 58-year-old man is found on laboratory testing to have a serum calcium level of 6.0 mg per deciliter (normal range, 8.5 to 10.5), an albumin level of 3.9 g per deciliter, and a phosphorus level of 6.0 mg per deciliter (normal range, 2.5 to 4.5). His medical history is notable only for long-standing hearing difficulties. He reports no history of neck surgery and is asymptomatic. His ionized calcium level is 0.75 mmol per liter (normal range, 1.10 to 1.32). How should his case be further evaluated and treated?

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
AKAliya A. Khan
Aliya A. Khan
JBJohn P. Bilezikian
John P. Bilezikian
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
BCBart L. Clarke
Bart L. Clarke
NGNeil J. Gittoes
Neil J. Gittoes
MMMichael Mannstadt
Michael Mannstadt
This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews. A formal process following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and the systematic reviews provided the structure for seven of the guideline recommendations. The task force used a less structured approach based on narrative reviews for 20 non-GRADEd recommendations. Clinicians may consider postsurgical HypoPT permanent if it persists for >12 months after surgery. To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long-term HypoPT. In individuals with nonsurgical HypoPT, genetic testing may be helpful in the presence of a positive family history of nonsurgical HypoPT, in the presence of syndromic features, or in individuals younger than 40 years. HypoPT can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataracts, seizures, cardiac arrhythmias, ischemic heart disease, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory indices. In patients with chronic HypoPT, the panel suggests conventional therapy with calcium and active vitamin D metabolites as first-line therapy (weak recommendation, low-quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers the use of PTH. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

1 October 2018 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JLJanet Y. Lee
Janet Y. Lee
DSDolores M. Shoback
Dolores M. Shoback

27 January 2020 in Annual Review of Medicine
Verified
Journal Article
Closed access
CCCheng Cheng
Cheng Cheng
KWKelly Wentworth
Kelly Wentworth
DSDolores M. Shoback
Dolores M. Shoback
Current osteoporosis medications reduce fractures significantly but have rare and serious adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their safety for long-term use. Insights from basic bone biology and genetic disorders have led to recent advances in therapeutics for osteoporosis. New approaches now in clinical use include the antisclerostin monoclonal antibody romosozumab, as well as the parathyroid hormone–related peptide analog abaloparatide. Clinical trial data show significant antifracture benefits with recently approved romosozumab. Studies using abaloparatide build on our longstanding experience with teriparatide and the importance of consolidating the bone mineral density gains achieved from an anabolic agent by following it with an antiresorptive. Combination and sequential treatments using osteoporosis medications with different mechanisms of action have also been tested with promising results. On the horizon is the potential for cell-based therapies (e.g., mesenchymal stem cells) and drugs that target the elimination of senescent cells in the bone microenvironment.

28 September 2011 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
MDMelita M Dvorak-Ewell
Melita M Dvorak-Ewell
TCTsui-Hua Chen
Tsui-Hua Chen
NLNathan Liang
Nathan Liang
CGCaitlin Garvey
Caitlin Garvey
BLBetty Liu
Betty Liu
DSDolores M Shoback
Dolores M Shoback
The extracellular Ca2+‐sensing receptor (CaR), a G protein‐coupled receptor responsible for maintenance of calcium homeostasis, is implicated in regulation of skeletal metabolism. To discern the role of the osteoblast CaR in regulation of bone development and remodeling, we generated mice in which the CaR is excised in a broad population of osteoblasts expressing the 3.6‐kb a1(I) collagen promoter. Conditional knockouts had abnormal skeletal histology at birth and developed progressively reduced mineralization secondary to retarded osteoblast differentiation, evident by significantly reduced numbers of osteoblasts and decreased expression of collagen I, osteocalcin, and sclerostin mRNAs. Elevated expression of ankylosis protein, ectonucleotide pyrophosphatase/phosphodiesterase 1, and osteopontin mRNAs in the conditional knockout indicate altered regulation of genes important in mineralization. Knockout of the osteoblast CaR also resulted in increased expression of the receptor activator of NF‐κB ligand (RANKL), the major stimulator of osteoclast differentiation and function, consistent with elevated osteoclast numbers in vivo. Osteoblasts from the conditional knockouts exhibited delayed differentiation, reduced mineralizing capacity, altered expression of regulators of mineralization, and increased ability to promote osteoclastogenesis in coculture experiments. We conclude that CaR signaling in a broad population of osteoblasts is essential for bone development and remodeling and plays an important role in the regulation of differentiation and expression of regulators of bone resorption and mineralization. © 2011 American Society for Bone and Mineral Research

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
JPJanice Pasieka
Janice Pasieka
KWKelly Wentworth
Kelly Wentworth
CYCaitlin T Yeo
Caitlin T Yeo
SCSerge Cremers
Serge Cremers
DDDavid Dempster
David Dempster
DSDolores M. Shoback
Dolores M. Shoback
The approach utilized a systematic review of the medical literature executed with specifically designed criteria that focused on the etiologies and pathogenesis of hypoparathyroidism. Enhanced attention by endocrine surgeons to new knowledge about parathyroid gland viability are reviewed along with the role of intraoperative parathyroid hormone (ioPTH) monitoring during and after neck surgery. Nonsurgical etiologies account for a significant proportion of cases of hypoparathyroidism (~25%), and among them, genetic etiologies are key. Given the pervasive nature of PTH deficiency across multiple organ systems, a detailed review of the skeletal, renal, neuromuscular, and ocular complications is provided. The burden of illness on affected patients and their caregivers contributes to reduced quality of life and social costs for this chronic endocrinopathy. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).